This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Keryx Biopharmaceuticals Inc (KERX)

NASDAQ: Health Care

Company Balance Sheet
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Assets
Cash and Equivalents 74.28M 55.70M 14.68M 35.25M
Receivables 882.00K 0.00 0.00 7.00K
Inventories 7.83M 0.00 0.00 0.00
Other Current Assets 4.09M 1.23M 430.00K 534.00K
Total Current Assets 98.60M 56.93M 15.11M 40.00M
Property, Plant & Equipment, Gross 2.72M 1.23M 879.00K 855.00K
Accumulated Depreciation & Depletion 1.18M 877.00K 823.00K 788.00K
Property, Plant & Equipment, Net 1.53M 349.00K 56.00K 67.00K
Intangibles 0.00 0.00 0.00 0.00
Other Non-Current Assets 292.00K 281.00K 198.00K 209.00K
Total Non-Current Assets 5.03M 3.84M 3.46M 3.48M
Liabilities & Shareholder Equity
Total Assets 103.63M 60.77M 18.57M 43.49M
Accounts Payable 24.15M 14.00M 7.21M 8.87M
Short Term Debt 0.00 0.00 0.00 0.00
Other Current Liabilities 0.00 0.00 0.00 0.00
Total Current Liabilities 29.31M 15.33M 8.04M 9.77M
Long Term Debt 0.00 0.00 0.00 0.00
Deferred Income Taxes 700.00K 0.00 0.00 0.00
Other Non-Current Liabilities 133.00K 38.00K 36.00K 2.67M
Minority Interest 0.00 0.00 0.00 0.00
Total Non-Current Liabilities 833.00K 38.00K 36.00K 2.67M
Total Liabilities 30.14M 15.37M 8.08M 12.44M
Preferred Stock Equity 0.00 0.00 0.00 0.00
Common Stock Equity 73.48M 45.40M 10.49M 31.05M
Common Par 93.00K 83.00K 72.00K 71.00K
Additional Paid In Capital 624.61M 485.01M 403.39M 401.22M
Cumulative Translation Adjustment 0.00 0.00 0.00 0.00
Retained Earnings -550.86M -439.34M -392.61M -369.89M
Treasury Stock -357.00K -357.00K -357.00K -357.00K
Other Equity Adjustments 0.00 0.00 0.00 0.00
Total Capitalization 73.48M 45.40M 10.49M 31.05M
Total Equity 73.48M 45.40M 10.49M 31.05M
Total Liabilities & Stock Equity 103.63M 60.77M 18.57M 43.49M
Total Common Shares Outstanding 92.68M 82.64M 71.92M 71.02M
Preferred Shares 0.00 0.00 0.00 0.00
Treasury Shares 79.95K 79.95K 79.95K 79.95K
Basic Weighted Shares Outstanding 91.00M 81.01M 71.63M 67.37M
Diluted Weighted Shares Outstanding 91.00M 81.01M 71.63M 67.37M
Number of Employees 155 41 25 29
Number of Part-Time Employees 0 0 0 0
KERX News

KERX Keryx Biopharmaceuticals Inc

Chart of KERX

Analysts Ratings for KERX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 7 8 9 9
Moderate Buy 0 0 0 0
Hold 1 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET KERX ANALYST REPORT

Brokerage Partners

KERX Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs